Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 4.1.1.28 - aromatic-L-amino-acid decarboxylase and Organism(s) Homo sapiens

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
6,7-dihydropteridine reductase deficiency
Cerebral folate deficiency.
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
6-pyruvoyltetrahydropterin synthase deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Abetalipoproteinemia
Vitamin-Responsive Movement Disorders in Children.
Addison Disease
Absence of autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease in girls and women with Turner syndrome.
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease.
Adenocarcinoma
Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors.
Carbidopa abrogates l-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.
Endocrine-related biochemistry in the spectrum of human lung carcinoma.
L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas.
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
Adenoma
Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.
Adenoma, Islet Cell
Clonal analysis of insulin and somatostatin secretion and L-dopa decarboxylase expression by a rat islet cell tumor.
Alzheimer Disease
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Anemia
Recent progress in gene therapy for Parkinson's disease.
Anemia, Hemolytic, Autoimmune
Influence of carbidopa, an aromatic amino acid decarboxylase inhibitor, on the development of autoimmune hemolytic anemia in NZB mice.
aromatic-l-amino-acid decarboxylase deficiency
3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
3-O-methyldopa levels in newborns: Result of newborn screening for aromatic l-amino-acid decarboxylase deficiency.
A comprehensive picture of the mutations associated with aromatic amino acid decarboxylase deficiency: from molecular mechanisms to therapy implications.
A female case of aromatic l-amino acid decarboxylase deficiency responsive to MAO-B inhibition.
A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency.
A novel compound heterozygous genotype associated with aromatic amino acid decarboxylase deficiency: Clinical aspects and biochemical studies.
A novel DDC gene deletion mutation in two Chinese mainland siblings with aromatic l-amino acid decarboxylase deficiency.
A rare cause of severe diarrhoea diagnosed by urine metabolic screening: aromatic L-amino acid decarboxylase deficiency.
A review of aromatic l-amino acid decarboxylase (AADC) deficiency in Taiwan.
AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients.
Abnormal glucose metabolism in aromatic l-amino acid decarboxylase deficiency.
Acceleration of rare disease therapeutic development: a case study of AGIL-AADC.
Anesthesia Management for Cesarean Delivery in a Woman With Aromatic L-Amino Acid Decarboxylase Deficiency: A Case Report.
Anesthesia management in a young child with aromatic l-amino acid decarboxylase deficiency.
Antisense oligonucleotides modulate dopa decarboxylase function in aromatic L-amino acid decarboxylase deficiency.
Aromatic amino acid decarboxylase deficiency in twins.
Aromatic amino Acid decarboxylase deficiency not responding to pyridoxine and bromocriptine therapy: case report and review of response to treatment.
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.
Aromatic Amino Acid Decarboxylase Deficiency: The Added Value of Biochemistry.
Aromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements.
Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma.
Aromatic L-amino acid decarboxylase deficiency in 17 Mainland China patients: Clinical phenotype, molecular spectrum, and therapy overview.
Aromatic l-amino acid decarboxylase deficiency in Taiwan.
Aromatic L-Amino Acid Decarboxylase Deficiency Is a Cause of Long-Fasting Hypoglycemia.
Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies.
Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation.
Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings.
Aromatic l-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies.
Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises.
Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis.
Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family.
Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.
Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology.
Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes.
Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis.
Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings.
Catecholamine toxicity in aromatic L-amino acid decarboxylase deficiency.
Cerebral folate deficiency.
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency.
Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic L-amino acid decarboxylase deficiency.
Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency.
Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations.
Clinical Profile and Outcome of Indian Children with Aromatic L-Amino Acid Decarboxylase Deficiency: A primary CSF Neurotransmitter Disorder Mimicking as Dyskinetic Cerebral Palsy.
Combined general and regional anesthetic in a child with aromatic L-amino acid decarboxylase deficiency.
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.
Detection of 3-O-methyldopa in dried blood spots for neonatal diagnosis of aromatic L-amino-acid decarboxylase deficiency: The northeastern Italian experience.
Diagnosis of aromatic l-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots.
Dopaminergic restoration of prefrontal cortico-putaminal network in gene therapy for aromatic l-amino acid decarboxylase deficiency.
Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial.
Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency.
Evaluation of 3-O-methyldopa as a biomarker for aromatic L-amino acid decarboxylase deficiency in 7 Brazilian cases.
Evaluation of comprehensive two-dimensional gas chromatography coupled to time-of-flight mass spectrometry for the diagnosis of inherited metabolic disorders using an automated data processing strategy.
Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons.
Gene therapy for aromatic L-amino acid decarboxylase deficiency.
Gene therapy for aromatic L-amino Acid decarboxylase deficiency.
Gene therapy for Parkinson's disease.
Gene therapy improves brain white matter in aromatic l-amino acid decarboxylase deficiency.
Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency.
Gene therapy with modified U1 small nuclear RNA.
Heterozygosis in aromatic amino acid decarboxylase deficiency: Evidence for a positive interallelic complementation between R347Q and R358H mutations.
Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.
Mammalian dopa decarboxylase: Structure, catalytic activity and inhibition.
Microstructural changes of brain in patients with aromatic L-amino acid decarboxylase deficiency.
Modified Frameless Stereotactic System for Intracerebral Delivery of Viral Vector in Young Children.
Molecular insights into the pathogenicity of variants associated with the aromatic amino acid decarboxylase deficiency.
Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan.
New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5'-Phosphate Decarboxylases.
Non-invasive urinary screening for aromatic L-amino acid decarboxylase deficiency in high-prevalence areas: a pilot study.
Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity.
Novel variants in aromatic L-amino acid decarboxylase deficiency: Case report of sisters with mild phenotype.
Pathobiochemical implications of hyperdopaminuria in patients with aromatic L-amino acid decarboxylase deficiency.
Pediatric neurotransmitter diseases.
Preimplantation and prenatal genetic diagnosis of aromatic L-amino acid decarboxylase deficiency with an amplification refractory mutation system-quantitative polymerase chain reaction.
Prevalence of Aromatic l-Amino Acid Decarboxylase Deficiency in At-Risk Populations.
Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states.
Recurrent Dystonic Crisis and Rhabdomyolysis Treated with Dantrolene in Two Patients with Aromatic L-Amino Acid Decarboxylase Deficiency.
Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency.
Report of Two Never Treated Adult Sisters with Aromatic L-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype?
S250F variant associated with aromatic amino acid decarboxylase deficiency: molecular defects and intracellular rescue by pyridoxine.
Semi-quantitative detection of a vanillactic acid/vanillylmandelic acid ratio in urine is a reliable diagnostic marker for aromatic L-amino acid decarboxylase deficiency.
Simultaneous measurement of monoamine metabolites and 5-methyltetrahydrofolate in the cerebrospinal fluid of children.
Sources and physiological significance of plasma dopamine sulfate.
Targeted cerebrospinal fluid analysis for inborn errors of metabolism on an LC-MS/MS analysis platform.
The genetic and clinical characteristics of aromatic L-amino acid decarboxylase deficiency in mainland China.
The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients.
The pediatric neurotransmitter disorders.
Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency.
Unusually mild phenotype of AADC deficiency in 2 siblings.
Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: The unsolved paradox.
Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer's Disease in the Transgenic CRND8 Mice.
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Urine organic acid as the first clue towards aromatic L-amino acid decarboxylase (AADC) deficiency in a high prevalence area.
Validating a rapid, real-time, PCR-based direct mutation detection assay for preimplantation genetic diagnosis.
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
Visualisation of impaired dopamine biosynthesis in a case of aromatic L-amino acid decarboxylase deficiency by co-registered 18F-FDOPA PET and magnetic resonance imaging.
Visualisation of impaired dopamine biosynthesis in a case of aromatic l-amino acid decarboxylase deficiency by co-registered( 18)F-FDOPA PET and magnetic resonance imaging.
Vitamin-Responsive Movement Disorders in Children.
Widening Phenotypic Spectrum of AADC Deficiency, a Disorder of Dopamine and Serotonin Synthesis.
Arrhythmias, Cardiac
Catecholamine toxicity in aromatic L-amino acid decarboxylase deficiency.
Ataxia
Vitamin-Responsive Movement Disorders in Children.
Autoimmune Diseases
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease.
Autoantibodies to human tryptophan hydroxylase and aromatic L-amino acid decarboxylase.
Basal Ganglia Diseases
Vitamin-Responsive Movement Disorders in Children.
Biotinidase Deficiency
Vitamin-Responsive Movement Disorders in Children.
Blindness
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Bradycardia
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
Brain Diseases
Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic L-amino acid decarboxylase deficiency.
Breast Neoplasms
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.
Bruxism
Experimental aggression and bruxism in rats.
Canavan Disease
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
Carcinoid Tumor
Aromatic L-amino acid decarboxylase (AAAD) inhibitors as carcinoid tumor-imaging agents: synthesis of 18F-labeled alpha-fluoromethyl-6-fluoro-m-tyrosine (FM-6-FmT).
Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors.
Observations on the substrate specificity of DOPA decarboxylase from ox adrenal medulla, human phaeochromocytoma and human argentaffinoma.
Carcinoma
Aromatic L-amino acid decarboxylase activities in human lung tissues: comparison between normal lung and lung carcinomas.
Effects of dibutyryl cyclic adenosine 3':5'-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase.
Immunohistochemical study of small cell lung carcinoma; with special reference to the neuroendocrine markers aromatic L-amino acid decarboxylase and gastrin-releasing peptide.
L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study.
L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures.
Nonhematopoietic tumor cells express functional GM-CSF receptors.
Polyamines are necessary for the survival of human small-cell lung carcinoma in culture.
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p.
Variable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implications.
Carcinoma, Hepatocellular
Human dopa decarboxylase: localization to human chromosome 7p11 and characterization of hepatic cDNAs.
Carcinoma, Medullary
Dopa decarboxylase in medullary carcinoma of the thyroid.
Carcinoma, Non-Small-Cell Lung
Interconversion of biological characteristics of small cell lung cancer depending on culture conditions.
Carcinoma, Renal Cell
L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.
Carcinoma, Small Cell
Nonhematopoietic tumor cells express functional GM-CSF receptors.
Carcinoma, Squamous Cell
L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study.
Cardiomyopathies
Increased gene expression of catecholamine-synthesizing enzymes in adrenal glands contributes to high circulating catecholamines in pigs with tachycardia-induced cardiomyopathy.
Catalepsy
Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
Cerebral Palsy
Clinical Profile and Outcome of Indian Children with Aromatic L-Amino Acid Decarboxylase Deficiency: A primary CSF Neurotransmitter Disorder Mimicking as Dyskinetic Cerebral Palsy.
Cholangiocarcinoma
Increased local dopamine secretion has growth promoting effects in cholangiocarcinoma.
Chorea
Treatment of Sydenham's chorea with a combination of L-dopa and a peripheral dopa decarboxylase inhibitor.
Choroideremia
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Classical Lissencephalies and Subcortical Band Heterotopias
Gene Profiling of Nucleus Basalis Tau Containing Neurons in Chronic Traumatic Encephalopathy: A Chronic Effects of Neurotrauma Consortium Study.
Colitis
Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake.
Color Vision Defects
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Colorectal Neoplasms
Revised Exon Structure of l-DOPA Decarboxylase (DDC) Reveals Novel Splice Variants Associated with Colorectal Cancer Progression.
Congenital Hyperinsulinism
Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
COVID-19
Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform.
Flight hormones as therapeutic target for novel Coronavirus infectious disease.
Cysts
Corrigendum: The Tryptophan decarboxylase 1 Gene From Aegilops variabilis No.1 Regulate the Resistance Against Cereal Cyst Nematode by Altering the Downstream Secondary Metabolite Contents Rather Than Auxin Synthesis.
The Tryptophan decarboxylase 1 Gene From Aegilops variabilis No.1 Regulate the Resistance Against Cereal Cyst Nematode by Altering the Downstream Secondary Metabolite Contents Rather Than Auxin Synthesis.
Dementia
Longitudinal study of striatal aromatic l-amino acid decarboxylase activity in patients with idiopathic rapid eye movement sleep behavior disorder.
Diabetes Mellitus, Type 1
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease.
Dyskinesias
A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.
Aromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements.
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Nurr1:RXR? heterodimer activation as monotherapy for Parkinson's disease.
Striatal mRNA expression patterns underlying peak dose l-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
[Juvenile Parkinson's disease initially presenting as bulbar incoordination: a case report]
[Onset-and end-of-dose dyskinesias induced by L-dopa treatment in a patient with juvenile parkinsonism]
Dystonia
A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.
Monoamine neurotransmitter deficiencies.
Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan.
When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center.
Epilepsy
Aromatic L-amino acid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements.
Equine Infectious Anemia
Recent progress in gene therapy for Parkinson's disease.
Fetal Growth Retardation
Intrauterine growth restriction induces up-regulation of cerebral aromatic amino acid decarboxylase activity in newborn piglets: [18F]fluorodopa positron emission tomographis study.
Genetic Diseases, Inborn
Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings.
Compound heterozygosis in AADC deficiency: A complex phenotype dissected through comparison among heterodimeric and homodimeric AADC proteins.
Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons.
New variants of AADC deficiency expand the knowledge of enzymatic phenotypes.
Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.
[Feeding difficulty and developmental delay for 8 months and nystagmus for 4 months in an infant].
Glioma
Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells.
Glomus Tumor
Non-FDG PET in the practice of oncology.
Graves Disease
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease.
guanidinoacetate n-methyltransferase deficiency
Targeted cerebrospinal fluid analysis for inborn errors of metabolism on an LC-MS/MS analysis platform.
Gyrate Atrophy
Targeted cerebrospinal fluid analysis for inborn errors of metabolism on an LC-MS/MS analysis platform.
Hemophilia A
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Hepatic Encephalopathy
Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.
Hepatitis
Serum aromatic L-amino acid decarboxylase activity in patients with acute hepatitis.
Hepatitis, Autoimmune
Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase.
Herpes Simplex
Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.
Herpes Zoster
Aromatic L-amino acid decarboxylase- and tyrosine hydroxylase-immunohistochemistry in the adult human hypothalamus.
The role of L-aromatic amino acid decarboxylase in serotonin-stimulated aldosterone secretion in response to salt intake.
Hyperalgesia
Delayed L-DOPA-induced hyperalgesia.
Hyperglycemia
Aminergic and thermoregulatory mechanims in hypothalamic regulation of growth hormone in cats.
Hyperglycinemia, Nonketotic
When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center.
Hyperhomocysteinemia
A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
Hyperprolactinemia
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia.
Hypersensitivity
A kinetic analysis of Drosophila melanogaster dopa decarboxylase.
[Studies on the significance of serotonin metabolism in allergic reaction. Changes in 5-hydroxytryptophan decarboxylase activity induced by the treatment with anti-serotonin and anti-allergic agents]
Hypertension
Aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, monoamine oxidase, malondialdehyde, and acid phosphatase in rat brain capillaries and kidney glomeruli in experimental hypertension.
Effects of depleting central and peripheral adrenaline stores on blood pressure in stroke-prone spontaneously hypertensive rats.
Involvement of dopamine in development of hypertension in spontaneously hypertensive rat: effect of carbidopa, inhibitor of peripheral dopa decarboxylase.
Pathophysiological role of dopamine on the development of hypertension in rats.
Hypoglycemia
Aromatic L-Amino Acid Decarboxylase Deficiency Is a Cause of Long-Fasting Hypoglycemia.
Hypophosphatemia, Familial
gamma-L-glutamyl-L-DOPA inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate.
Hypotension
Catecholamine toxicity in aromatic L-amino acid decarboxylase deficiency.
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
Hypotension, Orthostatic
Beneficial attenuating effect of L-threo-3,4-dihydroxyphenylserine on postural hypotension in anesthetized rats.
Idiopathic Pulmonary Fibrosis
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis.
Infections
Flight hormones as therapeutic target for novel Coronavirus infectious disease.
Probing the role of tryptophan-derived secondary metabolism in defense responses against Bipolaris oryzae infection in rice leaves by a suicide substrate of tryptophan decarboxylase.
The Tryptophan decarboxylase 1 Gene From Aegilops variabilis No.1 Regulate the Resistance Against Cereal Cyst Nematode by Altering the Downstream Secondary Metabolite Contents Rather Than Auxin Synthesis.
Insulinoma
Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen.
Intellectual Disability
Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant.
Kearns-Sayre Syndrome
Cerebral folate deficiency.
Laryngeal Neoplasms
l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer.
[Research of expression of L-DOPA decarboxylase in laryngeal cancer].
Learning Disabilities
The impact of caring for an individual with aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a conceptual model.
Lesch-Nyhan Syndrome
Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
Leukemia
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Leukodystrophy, Metachromatic
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
Lung Neoplasms
A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines.
Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture.
Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.
Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene.
Effects of dibutyryl cyclic adenosine 3':5'-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase.
Evaluation of biological characteristics of lung cancer by the human 28 kDa vitamin D-dependent calcium binding protein, calbindin-D28k.
IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines.
Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Interconversion of biological characteristics of small cell lung cancer depending on culture conditions.
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures.
Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.
Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells.
Relationships between neuroendocrine differentiation and sensitivity to gamma-radiation in culture line OH-1 of human small cell lung carcinoma.
The dynamic histopathologic spectrum of lung cancer.
Lymphoma
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Macular Degeneration
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Melanoma
A hepatic tumor associated with bilateral renal angiomyolipomas: a variant of angiomyolipoma?
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.
DOPA decarboxylase activity in a transplantable hamster melanoma.
Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
Targeted cerebrospinal fluid analysis for inborn errors of metabolism on an LC-MS/MS analysis platform.
Mevalonate Kinase Deficiency
Evaluation of comprehensive two-dimensional gas chromatography coupled to time-of-flight mass spectrometry for the diagnosis of inherited metabolic disorders using an automated data processing strategy.
Mitochondrial Diseases
Feasibility and Safety of Using Supraglottic Airway Devices for Pediatric Patients Undergoing Magnetic Resonance Imaging: A Case Series of High-Risk Patients.
Movement Disorders
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises.
Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Deriving Vignettes for the Rare Disease AADC Deficiency Using Parent, Caregiver and Clinician Interviews to Evaluate the Impact on Health-Related Quality of Life.
Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency.
Uptake of Pineal Gland Visible on 18F-DOPA PET/CT With Last Generation of SiPM PET/CT.
MPTP Poisoning
Quantitative [18F]fluorodopa/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs.
Mucopolysaccharidosis III
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
Muscle Hypotonia
Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan.
Muscular Atrophy
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Muscular Atrophy, Spinal
Gene therapy with modified U1 small nuclear RNA.
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
Muscular Dystrophy, Duchenne
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Myoclonus
The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
Myopathies, Structural, Congenital
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Neoplasm Micrometastasis
Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR.
Neoplasms
5-(2-18F-Fluoroethoxy)-L-Tryptophan as a Substrate of System L Transport for Tumor Imaging by PET.
Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture.
An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.
Aromatic L-amino acid decarboxylase activities in human lung tissues: comparison between normal lung and lung carcinomas.
Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors.
Biochemical composition of edge and center of malignant hamster insulinoma.
Carbidopa abrogates l-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Characteristics of cell lines established from human colorectal carcinoma.
Clonal analysis of insulin and somatostatin secretion and L-dopa decarboxylase expression by a rat islet cell tumor.
Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Comparative and quantitative study of L-dopa decarboxylase mRNA in rat neuronal and non-neuronal tissues.
Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors.
Endocrine-related biochemistry in the spectrum of human lung carcinoma.
Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone.
Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin.
Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin.
Fluorescence and electron microscopic histochemistry of endocrine-like cells in gastric mucosa and argyrophil tumor of Praomys (Mastomys) natalensis. Analysis of 5-hydroxytryptamine, histamine, Histidine decarboxylase, and aromatic amino acid decarboxylase.
Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression.
Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing approaches.
L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas.
l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer.
L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study.
Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers.
Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.
Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma.
Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
Neuroendocrine characteristics of human Leydig cell tumours.
PET in the diagnosis of neuroendocrine tumors.
Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2-[(18)F]fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging.
The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.
Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Variable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implications.
[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery.
[5-hydroxytryptophan decarboxylase activity in benign tumors in man]
[Current aspects of the pathology, diagnosis and therapy of C-cell carcinoma. A symposium held in Bonn, July 1991]
Nephrosis
Jejunal dopamine and Na,K+-ATPase activity in nephrotic syndrome.
Nervous System Diseases
Aromatic l-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies.
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease.
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.
Neuroblastoma
3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma.
Adrenergic enzymes in cultured mouse neuroblastoma: absence of detectable aromatic-L-amino-acid decarboxylase.
Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA.
Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor.
Evaluation of neurotropic drug actions on tyrosine hydroxylase activity and dopamine metabolism in clonal cell lines.
Impact of residual (18)F-fluoride in (18)F-FDOPA for the diagnosis of neuroblastoma.
Inhibition of catecholamine biosynthesis by carbidopa and metyrosine in neuroblastoma.
L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment.
Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Non-FDG PET in the practice of oncology.
Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states.
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Neurodegenerative Diseases
Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Neuroectodermal Tumors
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Neuroendocrine Tumors
Aromatic L-amino acid decarboxylase (AAAD) inhibitors as carcinoid tumor-imaging agents: synthesis of 18F-labeled alpha-fluoromethyl-6-fluoro-m-tyrosine (FM-6-FmT).
Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin.
Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis.
Non-FDG PET in the practice of oncology.
Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2-[(18)F]fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging.
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
Neuronal Ceroid-Lipofuscinoses
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions.
ornithine aminotransferase deficiency
Targeted cerebrospinal fluid analysis for inborn errors of metabolism on an LC-MS/MS analysis platform.
Osteosarcoma
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Papilloma
Characterization of bovine aromatic L-amino acid decarboxylase expressed in a mouse cell line: comparison with native enzyme.
Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex.
Parkinson Disease
6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.
A loss of Pdxk model of Parkinson disease in Drosophila can be suppressed by Buffy.
A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease.
A Rapid Non Invasive L-DOPA-(13)C Breath Test for Optimally Suppressing Extracerebral AADC Enzyme Activity - Toward Individualizing Carbidopa Therapy in Parkinson's Disease.
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.
Advances in the pharmacologic management of early Parkinson disease.
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine.
Aromatic L-amino acid decarboxylase modulation and Parkinson's disease.
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview.
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.
Clinical advantages of COMT inhibition with entacapone - a review.
Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Continuous subcutaneous lisuride infusions in Parkinson's disease.
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys.
Dopamine release via the vacuolar ATPase V0 sector c-subunit, confirmed in N18 neuroblastoma cells, results in behavioral recovery in hemiparkinsonian mice.
Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Effects of glutamate antagonists on the activity of aromatic L-amino acid decarboxylase.
Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease.
Entacapone. A review of its use in Parkinson's disease.
Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Fluorous l-Carbidopa Precursors: Highly Enantioselective Synthesis and Computational Prediction of Bioactivity.
Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease.
Identification by Virtual Screening and In Vitro Testing of Human DOPA Decarboxylase Inhibitors.
Inhibition in vitro of the enzymes of the oxidative pathway of tryptophan metabolism and of nicotinamide nucleotide synthesis by benserazide, carbidopa and isoniazid.
Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
Is DOPA a neurotransmitter?
Is L-dopa an endogenous neurotransmitter?
Kinetic characterization of the oxidation of carbidopa and benserazide by tyrosinase and peroxidase.
L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system.
l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.
l-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic l-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
L-dopa treatment and Parkinson's disease.
Liver function and gastric acid secretion in parkinsonian patients under prolonged treatment with L-dopa and a peripheral decarboxylase inhibitor.
Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models.
Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease.
Longitudinal study of striatal aromatic l-amino acid decarboxylase activity in patients with idiopathic rapid eye movement sleep behavior disorder.
Mammalian dopa decarboxylase: Structure, catalytic activity and inhibition.
Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease.
New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5'-Phosphate Decarboxylases.
Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases.
Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.
Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors.
Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies.
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Pharmacotherapy of Parkinson's disease.
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.
Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.
Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson's disease.
Sulfate and cysteine levels in the plasma of patients with Parkinson's disease.
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models.
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Toxicology and safety of COMT inhibitors.
Treatment of parkinson's disease with bromocriptine.
Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.
[Antiparkinsonian drugs]
[Gene therapy of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase genes in rat model of Parkinson's disease]
[Motor fluctuations in Parkinson disease: risk factors]
[Pharmacological treatments of Parkinson's disease]
[Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals]
[Recent therapeutic advances in geriatric neurology]
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor]
Parkinsonian Disorders
A pathogenic S250F missense mutation results in a mouse model of mild aromatic l-amino acid decarboxylase (AADC) deficiency.
Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease.
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism.
L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
Normalization of brain serotonin by L-tryptophan in levodopa-treated rats.
Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.
Sinemet and the treatment of Parkinsonism.
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]
[Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase]
[Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor]
[Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment]
Phenylketonurias
5-HYDROXYTRYPTOPHAN decarboxylase and phenylketonuria.
Cerebral folate deficiency.
Decreased 5-hydroxytryptophan decarboxylase activity in phenylketonuria.
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Pheochromocytoma
Activity of aromatic-L-amino-acid decarboxylase in pheochromocytoma cells.
Characterization of DOPA decarboxylase mRNA in rat pheochromocytoma.
Comparison of characteristics of bovine aromatic L-amino acid decarboxylase with human enzyme.
Different mRNAs code for dopa decarboxylase in tissues of neuronal and nonneuronal origin.
Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas.
Inhibition of aromatic L-aminoacid decarboxylase in clonal pheochromocytoma PC12h cells by N-methyl-4-phenylpyridinium ion (MPP+).
NSD-1015 alters the gene expression of aromatic L-amino acid decarboxylase in rat PC12 pheochromocytoma cells.
Preparation of a human DOPA decarboxylase cDNA probe by PCR and its assignment to chromosome 7.
Reduction of aromatic L-amino acid decarboxylase activity in clonal pheochromocytoma PC12h cells by culture in the presence of N-methyl-4-phenylpyridinium ion (MPP+).
Reduction of enzyme activity of tyrosine hydroxylase and aromatic L-aminoacid decarboxylase in clonal pheochromocytoma PC12h cells by carcinogenic heterocyclic amines.
Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation.
Simple purification of aromatic L-amino acid decarboxylase from human pheochromocytoma using high-performance liquid chromatography.
Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
[Purification and partial sequencing of L-dopa decarboxylase from pheochromocytoma in rats]
phosphoglycerate dehydrogenase deficiency
Cerebral folate deficiency.
Polyendocrinopathies, Autoimmune
Autoantibodies in autoimmune polyglandular syndrome type I patients react with major brain neurotransmitter systems.
Gastrointestinal immunity against tryptophan hydroxylase-1, aromatic L-amino-acid decarboxylase, AIE-75, villin and Paneth cells in APECED.
Prolactinoma
Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.
[Various aspects of dopaminergic function in patients with prolactin-secreting hypophyseal adenoma]
Propionic Acidemia
Evaluation of comprehensive two-dimensional gas chromatography coupled to time-of-flight mass spectrometry for the diagnosis of inherited metabolic disorders using an automated data processing strategy.
Prostatic Neoplasms
Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.
Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line.
Proteinuria
Blunted renal dopaminergic system activity in HgCl2-induced membranous nephropathy.
Pulmonary Fibrosis
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis.
Pure Autonomic Failure
Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
pyruvate dehydrogenase (nadp+) deficiency
Vitamin-Responsive Movement Disorders in Children.
Pyruvate Dehydrogenase Complex Deficiency Disease
Vitamin-Responsive Movement Disorders in Children.
REM Sleep Behavior Disorder
Longitudinal study of striatal aromatic l-amino acid decarboxylase activity in patients with idiopathic rapid eye movement sleep behavior disorder.
Restless Legs Syndrome
Levodopa for restless legs syndrome.
Retinitis Pigmentosa
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Rett Syndrome
Cerebral folate deficiency.
Rhabdomyolysis
Recurrent Dystonic Crisis and Rhabdomyolysis Treated with Dantrolene in Two Patients with Aromatic L-Amino Acid Decarboxylase Deficiency.
Rhabdomyosarcoma
Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.
Seizures
When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center.
[Action of some DOPA decarboxylase inhibitors with reference to different types of convulsions.]
sepiapterin reductase (l-erythro-7,8-dihydrobiopterin forming) deficiency
Urinary sulphatoxymelatonin as a biomarker of serotonin status in biogenic amine-deficient patients.
Small Cell Lung Carcinoma
Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene.
IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines.
Immunohistochemical study of small cell lung carcinoma; with special reference to the neuroendocrine markers aromatic L-amino acid decarboxylase and gastrin-releasing peptide.
Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.
Relationships between neuroendocrine differentiation and sensitivity to gamma-radiation in culture line OH-1 of human small cell lung carcinoma.
Spinal Cord Injuries
Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Spinal Cord Hemisection Facilitates Aromatic L-Amino Acid Decarboxylase Cells to Produce Serotonin in the Subchronic but Not the Chronic Phase.
Spinal cord injury enables aromatic L-amino acid decarboxylase cells to synthesize monoamines.
Synthesis, transport and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats.
Spinocerebellar Ataxias
Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures.
Squamous Cell Carcinoma of Head and Neck
L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study.
Stomach Neoplasms
Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR.
[Utility of dopa decarboxylase as a novel marker for the detection of peritoneal micro-metastases of gastric cancer with realtime RT-PCR]
Stupor
[Action of some inhibitors of L-DOPA decarboxylase on the duration of barbiturate narcosis in the mouse.]
succinate-semialdehyde dehydrogenase [nad(p)+] deficiency
Outcome of Patients With Inherited Neurotransmitter Disorders.
Teratoma
Neurochemical studies in a mouse teratoma with neuroepithelial differentiation. Presence of cyclic AMP, serotonin and enzymes of the serotonergic, adrenergic and cholinergic systems.
Thyroid Neoplasms
Levels of histaminase and L-DOPA decarboxylase activity in the transition from C-cell hyperplasia to familial medullary thyroid carcinoma.
Non-FDG PET in the practice of oncology.
The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.
Thyroiditis
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease.
Tourette Syndrome
New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5'-Phosphate Decarboxylases.
Tremor
Vitamin-Responsive Movement Disorders in Children.
Tuberous Sclerosis
Feasibility and Safety of Using Supraglottic Airway Devices for Pediatric Patients Undergoing Magnetic Resonance Imaging: A Case Series of High-Risk Patients.
Turner Syndrome
Absence of autoantibodies connected to autoimmune polyendocrine syndrome type I and II and Addison's disease in girls and women with Turner syndrome.
tyrosine 3-monooxygenase deficiency
Diagnosis and Treatment of Neurotransmitter Disorders.
Pediatric neurotransmitter diseases.
The pediatric neurotransmitter disorders.
Virus Diseases
Emerging Role of l-Dopa Decarboxylase in Flaviviridae Virus Infections.
Vitamin B 6 Deficiency
Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain.
Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in the developing rat liver and brain.
Instability of the apo form of aromatic L-amino acid decarboxylase in vivo and in vitro: implications for the involvement of the flexible loop that covers the active site.
The effect of pyridoxine deficiency on L-aromatic amino acid decarboxylase and tyrosine aminotransferase in developing brain.
Vitamin E Deficiency
Vitamin-Responsive Movement Disorders in Children.
Vitiligo
Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 1: epidermal H2O2/ONOO--mediated stress abrogates tryptophan hydroxylase and dopa decarboxylase activities, leading to low serotonin and melatonin levels.